Bifogade filer
PDF
Kurs
-5,77%
Likviditet
0,67 MSEK
Kalender
| Tid* | ||
| 2026-02-20 | 08:30 | Bokslutskommuniké 2025 |
| 2025-11-14 | 08:30 | Kvartalsrapport 2025-Q3 |
| 2025-08-15 | 08:30 | Kvartalsrapport 2025-Q2 |
| 2025-05-16 | 08:30 | Kvartalsrapport 2025-Q1 |
| 2025-02-21 | 08:30 | Bokslutskommuniké 2024 |
| 2024-10-31 | - | Kvartalsrapport 2024-Q3 |
| 2024-10-21 | - | Extra Bolagsstämma 2024 |
| 2024-08-23 | - | Kvartalsrapport 2024-Q2 |
| 2024-06-28 | - | Årsstämma |
| 2024-05-29 | - | Kvartalsrapport 2024-Q1 |
| 2024-05-17 | - | X-dag ordinarie utdelning CLS B 0.00 SEK |
| 2024-04-25 | - | Split CLS B 200:1 |
| 2024-02-23 | - | Bokslutskommuniké 2023 |
| 2023-11-17 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-25 | - | Kvartalsrapport 2023-Q2 |
| 2023-06-29 | - | Årsstämma |
| 2023-06-22 | - | X-dag ordinarie utdelning CLS B 0.00 SEK |
| 2023-06-08 | - | Extra Bolagsstämma 2023 |
| 2023-05-25 | - | Kvartalsrapport 2023-Q1 |
| 2023-02-23 | - | Bokslutskommuniké 2022 |
| 2022-11-22 | - | Extra Bolagsstämma 2022 |
| 2022-11-17 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-25 | - | Kvartalsrapport 2022-Q2 |
| 2022-06-29 | - | X-dag ordinarie utdelning CLS B 0.00 SEK |
| 2022-06-28 | - | Årsstämma |
| 2022-05-19 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-24 | - | Bokslutskommuniké 2021 |
| 2021-11-18 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-24 | - | Kvartalsrapport 2021-Q2 |
| 2021-06-29 | - | X-dag ordinarie utdelning CLS B 0.00 SEK |
| 2021-06-28 | - | Årsstämma |
| 2021-05-19 | - | Kvartalsrapport 2021-Q1 |
| 2021-03-31 | - | Extra Bolagsstämma 2021 |
| 2021-02-26 | - | Bokslutskommuniké 2020 |
| 2020-11-19 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-26 | - | Kvartalsrapport 2020-Q2 |
| 2020-06-12 | - | X-dag ordinarie utdelning CLS B 0.00 SEK |
| 2020-06-11 | - | Årsstämma |
| 2020-05-28 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-28 | - | Bokslutskommuniké 2019 |
| 2019-11-21 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-22 | - | Kvartalsrapport 2019-Q2 |
| 2019-06-12 | - | X-dag ordinarie utdelning CLS B 0.00 SEK |
| 2019-05-17 | - | Årsstämma |
| 2019-05-16 | - | Kvartalsrapport 2019-Q1 |
| 2019-03-18 | - | Extra Bolagsstämma 2019 |
| 2019-02-14 | - | Bokslutskommuniké 2018 |
| 2018-11-22 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-23 | - | Kvartalsrapport 2018-Q2 |
| 2018-06-20 | - | Årsstämma |
| 2018-06-14 | - | X-dag ordinarie utdelning CLS B 0.00 SEK |
| 2018-05-24 | - | Kvartalsrapport 2018-Q1 |
| 2018-05-18 | - | Extra Bolagsstämma 2018 |
| 2018-02-22 | - | Bokslutskommuniké 2017 |
| 2017-11-16 | - | Kvartalsrapport 2017-Q3 |
| 2017-07-17 | - | Kvartalsrapport 2017-Q2 |
| 2017-06-28 | - | X-dag ordinarie utdelning CLS B 0.00 SEK |
| 2017-06-27 | - | Årsstämma |
| 2017-05-18 | - | Kvartalsrapport 2017-Q1 |
| 2017-01-31 | - | Bokslutskommuniké 2016 |
| 2017-01-20 | - | Extra Bolagsstämma 2017 |
| 2016-11-17 | - | Kvartalsrapport 2016-Q3 |
| 2016-08-18 | - | Kvartalsrapport 2016-Q2 |
| 2016-06-16 | - | Årsstämma |
| 2016-05-19 | - | Kvartalsrapport 2016-Q1 |
| 2016-02-21 | - | Bokslutskommuniké 2015 |
| 2015-11-19 | - | Kvartalsrapport 2015-Q3 |
| 2015-08-20 | - | Kvartalsrapport 2015-Q2 |
| 2015-06-12 | - | X-dag ordinarie utdelning CLS B 0.00 SEK |
| 2015-06-11 | - | Årsstämma |
| 2015-05-21 | - | Kvartalsrapport 2015-Q1 |
| 2015-02-23 | - | Bokslutskommuniké 2014 |
| 2014-11-14 | - | Kvartalsrapport 2014-Q3 |
| 2014-08-20 | - | Kvartalsrapport 2014-Q2 |
| 2014-06-18 | - | X-dag ordinarie utdelning CLS B 0.00 SEK |
| 2014-06-17 | - | Årsstämma |
| 2014-05-22 | - | Kvartalsrapport 2014-Q1 |
| 2014-02-24 | - | Bokslutskommuniké 2013 |
| 2013-11-22 | - | Kvartalsrapport 2013-Q3 |
| 2013-09-19 | - | Extra Bolagsstämma 2013 |
| 2013-08-20 | - | Kvartalsrapport 2013-Q2 |
| 2013-06-10 | - | X-dag ordinarie utdelning CLS B 0.00 SEK |
| 2013-06-07 | - | Årsstämma |
| 2013-05-24 | - | Kvartalsrapport 2013-Q1 |
| 2013-02-25 | - | Bokslutskommuniké 2012 |
| 2012-11-23 | - | Kvartalsrapport 2012-Q3 |
| 2012-08-24 | - | Kvartalsrapport 2012-Q2 |
| 2012-06-08 | - | X-dag ordinarie utdelning CLS B 0.00 SEK |
| 2012-06-07 | - | Årsstämma |
| 2012-04-20 | - | Kvartalsrapport 2012-Q1 |
| 2012-01-09 | - | Bokslutskommuniké 2011 |
| 2012-01-04 | - | Extra Bolagsstämma 2012 |
| 2011-11-21 | - | Kvartalsrapport 2011-Q3 |
| 2011-09-26 | - | Kapitalmarknadsdag 2010 |
| 2011-08-22 | - | Kvartalsrapport 2011-Q2 |
| 2011-06-10 | - | Årsstämma |
| 2011-05-20 | - | Kvartalsrapport 2011-Q1 |
| 2011-02-24 | - | Bokslutskommuniké 2010 |
| 2010-11-24 | - | Kvartalsrapport 2010-Q3 |
| 2010-08-25 | - | Kvartalsrapport 2010-Q2 |
| 2010-05-28 | - | X-dag ordinarie utdelning CLS B 0.00 SEK |
| 2010-05-26 | - | Kvartalsrapport 2010-Q1 |
| 2010-02-26 | - | Bokslutskommuniké 2009 |
| 2009-11-30 | - | Kvartalsrapport 2009-Q3 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Lund, Sweden - Clinical Laserthermia Systems AB (publ) ("CLS" or the "Company") today announces that the Company's new Board member Peter Mantas, the CEO, Dan J. Mogren, and EVP Operations, Jimmy Johansson, have purchased a total of 22,000 Class B shares in CLS.
Peter Mantas acquired 10,000 shares bringing his total holding to 10,000 Class B shares on Wednesday, November 6th.
Dan J. Mogren completed the purchase of 8,000 shares on November 5th. After the transactions, Dan J. Mogren's total holding amounts to 30,939 Class B shares plus 632 Class B shares via Medinovus AB.
Jimmy Johansson acquired 4,000 shares through his company Medtech Öresund AB on Thursday, October 31st. After the transactions, Jimmy Johansson's total holding amounts to 429 Class B shares plus 25,608 Class B shares via Medtech Öresund AB.
The shares were purchased in ongoing trading on Nasdaq First North Growth Market Stockholm.
For more information, please contact:
Dan J. Mogren, CEO, Clinical Laserthermia Systems AB (publ)
Phone: +46 (0) 70-590 11 40
E-post: dan.mogren@clinicallaser.com
About CLS
Clinical Laserthermia Systems AB (publ), develops and sells TRANBERG®|Thermal Therapy System and ClearPoint Prism Neuro Laser Therapy System with sterile disposables, for minimally invasive treatment of cancer tumors and drug-resistant epilepsy. The products are marketed and sold through partners for image-guided laser ablation and are used in studies for treatment with imILT®, the company's interstitial laser thermotherapy for immune stimulating ablation with potential abscopal treatment effect. CLS is headquartered in Lund, Sweden, with subsidiaries in Germany, the United States and a marketing company in Singapore. CLS is listed on Nasdaq First North Growth Market under the symbol CLS B. Certified adviser (CA) is FNCA Sweden AB.
For more information about CLS, please visit the Company's website: www.clinicallaser.se